To find out more about a company click on the company name to see a brief profile.

Tumor Ticker Top 5 Winners

SUPG $3.23 0.29 +8.98%
OGXI $20.38 1.70 +8.34%
CYTR $1.25 0.10 +8%
ABII $37.87 2.49 +6.58%
DCTH $6.05 0.38 +6.28%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Tumor Ticker Top 5 Losers

BVTI.PK $1.18 -0.27 -22.88%
CTIC $1.00 -0.09 -9%
MITI $7.54 -0.49 -6.5%
PPHM $3.42 -0.11 -3.22%
ZIOP $3.73 -0.11 -2.95%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.





Current Articles  |  Archived Articles

Articles From The Most Current Issue of OBR

The Ongoing Hopes and Challenges of Cancer Vaccines (Part 2 of 2)

Mon, Mar 01, 2010
In Part 1, the pitfalls of clinical development of cancer immunotherapy research was examined. In Part 2, cancer vaccine commercialization challenges are discussed as are recommendations for overcoming the obstacles to bring one of these innovative therapies to market.
[ read article ]

Managing the Health of Your Patients and Your Practice

Mon, Mar 01, 2010
Good patient care goes hand in hand with the good financial standing of an oncology practice. Health information technology (HIT) plays an important role in providing oncologists with resources and tools they need to optimize the health of their patients. Mike Kelly of McKesson Specialty Group presents solutions on how to optimize HIT to help practices in today’s environment.
[ read article ]

Risk-Sharing Schemes in Oncology—Future or Fad?

Mon, Mar 01, 2010
In past issues, OBR has explored how oncologists will be paid in a reformed healthcare system. In July ’09 we discussed the episode-based payment system as an alternative to the current buy and bill model for reimbursement. For this issue, we continue to delve into this subject matter, but this time we are analyzing “risk-sharing” and gaining perspective on the role that these patient-access schemes could play in helping maintain quality of cancer care in the United States.
[ read article ]

A Perspective on Cancer Drug Pricing and Volume

Mon, Mar 01, 2010
Despite bringing innovative therapies to market, manufacturers are often at the center of the criticism regarding the high cost of cancer care. What is it that drives up the cost of care? An analysis of five-year drug pricing trends for 11 high-volume cancer agents reveals surprising results.
[ read article ]

OBR Radar: Keeping an Eye on Projected Market Moving Events in the Oncology Pipeline

Mon, Mar 01, 2010
In the latter portion of ’09 we saw fascinating clinical advances and failures. What does ’10 hold for us in the near term? We dig deeper into OBR Radar and OBR daily to uncover some near-term events of interest.
[ read article ]

ON-CURRENCES

Mon, Mar 01, 2010
Tracking the movement of oncology business personnel and other news making events in the oncology community.
[ read article ]